Inve India ▾

Anthem Biosciences share price & results

Anthem Biosciences Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Bengaluru CRDMO — drug discovery, development & manufacturing plus a specialty ingredients business.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue384 ₹ crore−28.6% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin34.0 %−2.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit102 ₹ crore−31.1% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity21.75 %+1.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin29.99 %+29.3 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)-2.15 %−14.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

4 of 4 judged targets kept · 10 open · verdicts reflect calls analysed to Q1 FY27.

Anthem Biosciences Limited management guidance track record on Inve: 14 targets tracked across analysed earnings calls (4 achieved, 0 missed, 10 open).

TargetOriginal wordingSaidLatest callVerdict
Revenue Growth (YoY)about 20% growth on a year-on-year basis
Call transcript, Q1 FY26 · 14 Aug 2025		Q1 FY26Q1 FY27:Promise pertains to FY26, which is complete. Final verdict stands.
Call transcript, Q1 FY27 · 22 Jul 2026		Achieved*
Revenue Growth (YoY)in the vicinity of 20% and more... in the coming years
Call transcript, Q4 FY26 · 20 May 2026		Q4 FY26Q1 FY27:Q1 FY27 revenue declined YoY due to timing shifts. Management now guides for 'double-digit' growth for the full year, a softer tone than the original '20% and more' aspiration.
Call transcript, Q1 FY27 · 22 Jul 2026		At Risk
Unit-4 Phase 1 Commissioningconsistently commissioned in two years from now
Call transcript, Q2 FY26 · 10 Nov 2025		Q2 FY26Q1 FY27:Timeline reaffirmed. Management states Unit 4 will be ready by the end of FY28, consistent with the original target.
Call transcript, Q1 FY27 · 22 Jul 2026		On Track

Source: Inve Guidance Tracker for Anthem Biosciences Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

10 of Anthem Biosciences Limited's 14 targets are still open. See which are on track and which have gone quiet. The 3 above are the free sample; 11 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹837.15 +1.81% · +₹14.9

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +16.3% 1Y

₹600₹700₹800₹900Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 10 Nov 2025Q3 FY26 — 5 Feb 2026Q4 FY26 — 20 May 2026Q1 FY27 — 22 Jul 2026

1Y: ₹719.95 on 24 Oct 2025 → ₹837.15. High ₹957.8 (8 Sept 2026), low ₹587.85 (1 Feb 2026).

Previous close
₹822.25
Market cap
₹47.1k Cr
52-week range
₹587.85 – ₹957.8
One year
+14.50%
Price to earnings (TTM to Jun 2026)
79.50×
Return on equity (TTM to Jun 2026)
21.75%

Overview

Symbol
NSE:ANTHEM
Exchange
NSE
Currency
INR

What Anthem Biosciences Limited does

Based on the company's own presentations, annual report and earnings calls.

Anthem Biosciences is an integrated Contract Research, Development and Manufacturing Organisation (CRDMO) that provides drug discovery, development and manufacturing services to global biotech and pharmaceutical companies, working with both New Chemical Entities (NCEs) and New Biological Entities (NBEs) from preclinical through commercial-scale production. Alongside this, it runs a Specialty Ingredients business manufacturing probiotics, enzymes, nutritional actives, APIs, vitamin analogues and biosimilars for pharmaceutical and nutrition customers. It earns fee-for-service and manufacturing revenue by executing discovery-to-commercialisation projects for global biopharma customers and by supplying specialty ingredient products. Its technology platforms span RNA interference, antibody-drug conjugates, peptides, lipids and oligonucleotides, built on in-house custom synthesis, fermentation and biotransformation manufacturing capabilities.

Segments

  • CRDMO
  • Specialty Ingredients
Manufacturing facilities
3 cGMP facilities in Karnataka (Bommasandra Unit I; Harohalli Units II and III/NeoAnthem), plus a new Unit IV greenfield facility under construction at Harohalli
Custom synthesis capacity
425 KL
Fermentation capacity
142 KL
Commercial molecules manufactured
14
Cumulative customers served
675+
Cumulative projects executed
8,000+
Founded 2006Headquarters Bommasandra, Bengaluru, Karnataka, IndiaEmployees 2,282 (March 31, 2026) Company website

How the price took the results

close before → close after

Q1 FY27
−1.6%
22 Jul
Q4 FY26
−0.9%
20 May
Q3 FY26
+4.9%
5 Feb
Q2 FY26
+1.2%
10 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Anthem Biosciences Limited

Free account: one company. Everything above stays public.

Write why you follow Anthem Biosciences Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Anthem Biosciences Limited

Guides on how to read this kind of business and the numbers that matter.